TNF and diabetes mellitus: Subclinical inflammation, including certain interleukins (IL), CRP, or tumor necrosis factor-α (TNF-α), seems to play an extremely important role in the development and progression of DPN, an interaction that may lead not only to methods for preventing DM complications but also to the development of new drug therapies [17,19,20].